Erythema annulare centrifugum

Erythema Annulare Centrifugum in a Patient with Chronic Myeloid Leukaemia on Ponatinib

“…However, sometimes no causative agent can be identifi ed. 2 In our patient, the EAC appeared years after the diagnosis of CML but it was present after switching to ponatinib from imatinib. Hence, it seems logical to Keywords: chronic myeloid leukaemia, erythema annulare centrifugum, ponatinib…”

More data on erythema annulare centrifugum induced by COVID ‐19 vaccination

“… 4 EAC is considered to be a hypersensitivity reaction to a wide range of potential triggers, including infections, malignancies, foods, drugs, and vaccines. 5 Interestingly, both immediate (type I) and delayed (type IV) hypersensitivity reactions have been reported in association with COVID‐19 vaccination. 2 Other possible pathomechanisms of SARS‐CoV‐2 induced cutaneous lesions include mechanisms of molecular mimicry caused by genetic similarities between SARS‐CoV‐2 spike protein components to cross‐reactive human antigens leading to autoreactive lymphocytes or cross‐reactive human antigens, functional angiopathies, or reactivation of viral infections.…”

Uncommon non-infectious annular dermatoses

“…EAC is clinically characterized by the presence of annular erythematous lesions that enlarge centrifugally with central clearing. [ 3 4 ] A fine scale may be present inside the advancing edge, defined trailing scale. The lesions, in most of the cases, involve the extremities, in particular, thighs and legs, and less frequently, the trunk.…”

“…The lesions, in most of the cases, involve the extremities, in particular, thighs and legs, and less frequently, the trunk. [ 3 4 ] The peak incidence is mid-adult life, with no gender difference. EAC superficial type is clinically characterized by the presence of lesions with non-indurated borders that are scaly and itchy [ Figure 1a ].…”

“…Other fewer associations include Crohn's disease, pregnancy, autoimmune endocrinopathies, and hypereosinophilic syndrome. [ 3 4 5 ] The treatment of EAC is based on topical corticosteroids and a brief course of systemic corticosteroids. In the case of EAC associated with an underlying disorder, the treatment of the other disease leads to a faster disappearance and resolution of the lesions.…”